Tenax CEO Christopher Giordano Buys 10,850 Shares

What Happened
Christopher (Chris) Giordano, CEO and director of Tenax Therapeutics, made two open‑market purchases of company stock (transaction code P). On 2026-09-11 he acquired 6,000 shares (reported value $11,250; reported price shown as $1.88, see footnote), and on 2026-09-15 he acquired 4,850 shares (reported value $8,837; reported price shown as $1.82). Combined, the purchases totaled 10,850 shares for approximately $20,087. These were purchases (not sales), which insiders often view as a signal of confidence, though motivations are not stated.

Key Details

• Transaction dates & prices:
  • 2026-09-11: 6,000 shares, reported price $1.88, reported value $11,250. (F1: executed in multiple trades at $1.87–$1.88; Column 4 shows a weighted average.)
  • 2026-09-15: 4,850 shares, reported price $1.82, reported value $8,837. (F2: executed in multiple trades at $1.82–$1.83; Column 4 shows a weighted average.)
• Total bought: 10,850 shares for ~$20,087.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Notable footnotes: F1 and F2 explain weighted-average pricing across multiple trades; the filing also includes several option-vesting footnotes (F3–F7) describing existing option schedules, though those are not transactions here.
• Timeliness: Form 4 was filed 2026-09-15 (reporting period includes the 2026-09-11 and 09-15 trades). The filing date is within the SEC’s required reporting window for these transactions.

Context
These were straightforward open‑market purchases (P). The filing does not indicate any option exercises, gifts, or sales tied to these trades. Because the filing lists option-vesting schedules elsewhere (F3–F7), the insider holds other equity/derivative awards, but the two items reported here are cash purchases of common stock.